GOLDMAN SACHS GROUP INC - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 455 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.01 and the average weighting 0.2%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$90,053,342
-18.9%
742,892
-23.4%
0.02%
-18.2%
Q2 2023$111,002,886
-18.4%
969,288
-1.8%
0.02%
-24.1%
Q1 2023$136,020,507
-18.6%
986,872
-23.5%
0.03%
-23.7%
Q4 2022$167,070,954
+33.0%
1,289,327
+13.4%
0.04%
+31.0%
Q3 2022$125,650,000
+15.5%
1,136,693
-21.7%
0.03%
+16.0%
Q2 2022$108,821,000
+50.7%
1,451,723
+57.1%
0.02%
+66.7%
Q1 2022$72,188,000
-26.1%
924,056
-14.8%
0.02%
-21.1%
Q4 2021$97,642,000
+11.0%
1,084,305
+14.0%
0.02%
+5.6%
Q3 2021$87,957,000
+16.9%
951,095
-1.8%
0.02%
+12.5%
Q2 2021$75,261,000
+18.8%
968,099
+13.9%
0.02%
+6.7%
Q1 2021$63,366,000
-76.7%
850,212
-46.7%
0.02%
-78.6%
Q4 2020$272,207,000
+15.8%
1,596,617
-4.6%
0.07%
+6.1%
Q3 2020$235,077,000
-13.5%
1,673,981
-1.2%
0.07%
-19.5%
Q2 2020$271,759,000
+37.1%
1,694,888
-16.3%
0.08%
+17.1%
Q1 2020$198,181,000
-11.1%
2,025,972
+17.3%
0.07%
+25.0%
Q4 2019$222,959,000
+92.6%
1,727,820
+12.4%
0.06%
+69.7%
Q3 2019$115,781,000
-20.6%
1,537,198
+60.1%
0.03%
-21.4%
Q2 2019$145,899,000
+21.1%
960,180
-5.0%
0.04%
+16.7%
Q1 2019$120,450,000
+64.2%
1,010,573
+50.3%
0.04%
+56.5%
Q4 2018$73,357,000
-26.0%
672,204
+9.5%
0.02%
-11.5%
Q3 2018$99,110,000
-14.4%
613,644
-29.9%
0.03%
-16.1%
Q2 2018$115,752,000
+128.8%
875,714
+28.2%
0.03%
+138.5%
Q1 2018$50,598,000
+15.0%
682,929
-13.6%
0.01%
+18.2%
Q4 2017$44,001,000
-24.2%
790,815
-38.2%
0.01%
-21.4%
Q3 2017$58,046,000
+106.7%
1,279,663
+53.6%
0.01%
+100.0%
Q2 2017$28,079,000
+49.0%
832,968
+30.8%
0.01%
+40.0%
Q1 2017$18,851,000
+70.9%
636,892
+58.4%
0.01%
+66.7%
Q4 2016$11,030,000
-70.5%
402,063
-33.9%
0.00%
-72.7%
Q3 2016$37,349,000
+126.1%
608,183
-29.8%
0.01%
+120.0%
Q2 2016$16,517,000
+139.9%
866,176
+145.6%
0.01%
+150.0%
Q1 2016$6,885,000
-21.2%
352,727
+55.8%
0.00%
-33.3%
Q4 2015$8,735,000
+84.2%
226,385
+53.3%
0.00%
+200.0%
Q3 2015$4,742,000
+40.6%
147,699
+33.3%
0.00%0.0%
Q2 2015$3,372,000
+162.6%
110,808
+14.6%
0.00%
Q1 2015$1,284,000
+2.0%
96,661
+11.1%
0.00%
Q4 2014$1,259,000
-83.0%
86,981
-75.2%
0.00%
-100.0%
Q3 2014$7,415,000
+359.4%
351,424
+548.7%
0.00%
Q2 2014$1,614,000
-23.8%
54,176
-38.6%
0.00%
Q1 2014$2,119,000
-61.9%
88,168
-67.7%
0.00%
-100.0%
Q4 2013$5,555,000
-34.7%
272,748
+51.5%
0.00%
-33.3%
Q3 2013$8,503,000
+53.6%
180,035
+23.7%
0.00%
+50.0%
Q2 2013$5,537,000
+2236.3%
145,565
+1483.6%
0.00%
Q4 2012$237,000
-78.5%
9,192
-87.0%
0.00%
Q3 2012$1,100,00070,8050.00%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Sonic Fund II, L.P. 112,689$14,541,00014.93%
Casdin Capital, LLC 670,000$86,457,0007.95%
Logos Global Management LP 226,002$29,163,0007.19%
Avoro Capital Advisors LLC 1,760,000$227,110,0006.67%
Camber Capital Management LP 600,000$77,424,0003.94%
STANSBERRY ASSET MANAGEMENT, LLC 71,133$9,179,0003.74%
Eventide Asset Management 996,000$128,524,0003.62%
CADIAN CAPITAL MANAGEMENT, LP 550,000$70,972,0003.14%
RTW INVESTMENTS, LP 605,762$78,168,0002.95%
Consonance Capital Management LP 356,145$45,957,0002.80%
View complete list of SAREPTA THERAPEUTICS INC shareholders